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Abstract: There are currently >75,000 feral horses (Equus ferus caballus) and burros

(E. asinus) on U.S. public lands, yet the Appropriate Management Level (AML) is set at just under
27,000. Wildlife managers, conservation biologists, and livestock ranchers are concerned about
the impacts that these free-ranging horses have on shared rangelands. Immunocontraceptive
vaccines may have the greatest potential to regulate horse population numbers once AML is
reached; however, the vaccine must have multi-year eﬃcacy to be both technically feasible and
cost-eﬀective. Immunocontraception based on porcine zona pellucida (PZP)-speciﬁc antigens is
highly tissue-speciﬁc, targeting the ova, and blocking sperm binding through antibody occupation
of ZP receptors on the ova. ZonaStat-H and PZP-22 are PZP-based vaccines; however, their
contraceptive eﬃcacy does not last long enough to meet management needs. SpayVac®
achieves multi-year eﬃcacy with a single dose, without boosters, because the PZP antigens are
encapsulated within liposomes (multi-layered, submicroscopic vesicles), which gradually release
PZP glycoproteins to antigen-presenting cells over an extended period of time. We review results
from SpayVac trials in horses and other species to deepen our understanding of how the vaccine
works and how it may best be applied to regulate free-ranging horse populations at AML. We
examine 3 studies in horses, which used diﬀerent SpayVac formulations and delivery methods,
to learn more about the relationship between antibody titers and contraceptive eﬃcacy, as well
as potential mechanisms of action (e.g., preferential stimulation of IgG4/7 antibody isotypes).
Additional research to explore possible eﬀects of injection site location, antigen purity, role
of PZP antibodies, and diﬀerent formulations (e.g., dose, adjuvant) is needed for eﬃcacious
application to free-ranging herds.
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Managing populations of free-ranging
horses (Equus ferus caballus) and burros (E.
asinus) is a significant challenge, involving
animal-welfare, environmental, sociological,
public policy, and economic dimensions. These
non-native equids have few native predators,
which contributes to high survivorship
rates and annual population growth rates of
15–20% (Garrott 2018). Wildlife managers,
conservation biologists, and cattle ranchers
have concerns about the impacts that freeranging horses have on rangelands shared by
native ungulates and domestic stock (Danvir
2018). Salter and Hudson (1980), in a study of
the spatial and foraging relationships among
horses, elk (Cervus canadensis), mule deer
(Odocoileus hemionus), moose (Alces alces), and

cattle (Bos taurus), found the greatest potential
for resource competition was between horses
and cattle, with a 66% overlap in their summer
diets, although the contemporaneous spatial
overlap was less. Ostermann-Kelm et al. (2009)
found that free-ranging horses in a desert
environment in California compacted soils,
increased erosion, and decreased plant cover.
Free-ranging horse populations that inhabit
federal lands in the western United States are
protected by the Wild Free-Roaming Horses
and Burros Act (WFRHBA) of 1971 (Public Law
92-195), which requires the Bureau of Land
Management (BLM) to manage the populations
“…to achieve and maintain a thriving natural
ecological balance…” By the summer of 2017,
the numbers on public lands had increased
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to >75,000 (D. Bolstad, BLM, personal
communication), far exceeding the Appropriate
Management Level (AML), which is currently
set at 26,715 (BLM 2018).
Under the original WFRHBA, the BLM was
permitted to humanely kill excess horses, and
from 1981–1982, 47 horses were euthanized.
However, the resulting public outcry eﬀectively
ended the further killing of healthy horses
(Garrott 2018). Younger horses may be adopted
by members of the public, but about half of the
84,741 horses removed between 2000 and 2009
ended up in long-term holding (Vincent 2010).
At present, the oﬀ-range population is >45,000
horses and costs approximately $50 million per
year to maintain (Garrott 2018). Considering
the costs of capture and transportation, and
a captive lifespan of 15 years (Garrott and
Oli 2013), each horse maintained in an oﬀrange facility costs taxpayers close to $25,000.
Accommodating the present captive population
will have a final cost of approximately $1.25
billion. However, this does not include the
additional estimated 50,000 horses currently on
the range that exceed the AML.
Contraception has been recognized as a
potentially useful approach for controlling
the fertility of free-ranging horse populations,
thus reducing or possibly even eliminating
the need to remove horses from their natal
ranges (Kirkpatrick and Rutberg 2001, National
Research Council 2013). Contraception eﬀorts
for free-ranging populations have focused
primarily on females because a single fertile male
can inseminate numerous females (Garrott and
Siniﬀ 1992). Several contraceptive techniques
have been tried in horses, including hormone
implants (Plotka et al. 1988), intrauterine
devices (Killian et al. 2008), and more recently,
permanent non-surgical methods of sterilization
that target specific reproductive organs or
functions (e.g., equine maternal recognition of
pregnancy; Swegen and Aitken 2016, Hall et al.
2017). Surgical sterilization, such as ovariectomy,
is highly invasive and less cost-eﬀective as a
population management tool. Animal welfare
issues are also raised by conducting surgeries
under field conditions.
Immunocontraceptive vaccines may have
the greatest potential to help the BLM regulate
horse populations at the AML; however, a
vaccine must have multi-year eﬃcacy to be
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both technically feasible and cost-eﬀective
(National Research Council 2013). Two main
classes of contraceptive vaccines have been
developed based on gonadotropin-releasing
hormone (GnRH) and porcine zona pellucida
(PZP) antigens. In this paper, we briefly review
these classes of contraceptive vaccines prior to
focusing on SpayVac’s performance in several
species over the past 20 years, and we end with
a discussion about future research needed to
maximize SpayVac’s performance in the field.

GnRH vaccines
The GnRH vaccines have met varying
degrees of success in a variety of species.
The GnRH is a hormone produced in the
hypothalamus, and its eﬀect on reproduction
is primarily via the pituitary gland, which
secretes additional hormones in response
to binding GnRH (e.g., follicle-stimulating
hormone, luteinizing hormone). It is these
hormones that subsequently aﬀect the gonads,
secondary sexual characteristics, and behavior.
Serum concentrations of GnRH normally start
increasing at the onset of puberty (Wiemann
et al. 1989), so age of the animal at the time of
GnRH vaccine administration is an important
consideration. For example, a juvenile (7-yearold) Asian bull elephant (Elephas maximus) that
received multiple GnRH boosters over the
course of 6 years demonstrated stunted growth
in addition to diminished size of reproductive
glands and penile atrophy (Lueders et al. 2014).
In 2009, the U.S. Department of Agriculture,
National Wildlife Research Center obtained
U.S. Environmental Protection Agency (EPA)
regulatory approval for the use of GonaCon™
in deer, and a second version was approved for
use in horses in 2013. GnRH vaccines typically
require boosters and result in suppressed
reproduction and reproductive behavior in a
variety of species, including horses (Elhay et
al. 2007) as well as zebras (E. zebra) and African
elephants (Loxodonta africana; Botha et al. 2008).
Baker et al. (2017) found that a single injection
of GonaCon in mares (n = 29) resulted in a
36% (P < 0.047) and 31% (P < 0.053) decrease
in foaling compared to controls (n = 28) during
years 2 and 3 post-injection, respectively.
Eﬀects of GnRH vaccination on reproduction
have been variable by species as well as gender.
For example, Valades et al. (2012) found that
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Improvac® (GnRH-based vaccine produced
overseas) was not able to aﬀect the estrous
cycle of female African elephants; yet the
same vaccine significantly decreased testicular
and accessory sex gland sizes in bull African
elephants (Lueders et al. 2017). Importantly,
GnRH vaccines may have serious side eﬀects
(Kirkpatrick et al. 2011) because GnRH receptors
are located in a variety of tissues in addition to
reproductive organs, including the nervous
system (Lopez et al. 2002), bladder (Bahk et al.
2008), and heart (Skinner et al. 2009). Studies
have not focused on these potential side eﬀects.

PZP vaccines
In contrast, immunocontraception based
on PZP-specific antigens is highly tissuespecific, targeting primarily the ova, and
is thought to block sperm binding through
antibody occupation of ZP receptors on the
ova (Dunbar and Schwoebel 1988, Skinner et al.
1990, Benoﬀ 1997). When a sperm attaches to
the ZP, the acrosome reaction is initiated and
fertilization ensues (Bedford 2008). While this
is likely the primary mechanism of action for
PZP vaccines, other mechanisms have been
suggested, including autoimmune oophoritis
in dogs (Canis lupus familiaris; Brandon et al.
1998) and direct eﬀects on the ovary resulting
in an absence of growing follicles in sheep (Ovis
spp.; Stoops et al. 2006) and horses (Bechert et
al. 2013). Zona antibodies may disrupt cellular
communication
between
diﬀerentiating
follicular cells and the developing oocyte, and
this may lead to the destruction of a portion or
all of the oocyte pool (Skinner et al. 1984). Most
PZP vaccines are made with partially purified
porcine ZP, and other follicular proteins could
potentially be involved in eliciting ovarian
responses in vaccinates (Stoops et al. 2006).
Because PZP is a weak immunogen, a
powerful adjuvant is required to stimulate an
immune response. The AdjuVac™ adjuvant
uses Mycobacterium avium in mineral oil (Miller
et al. 2004). However, the most commonly used
adjuvant at present for many contraceptive
vaccines, including SpayVac, is Modified
Freund’s Adjuvant (MFA), which is made with
fractionated cell walls from Mycobacterium
butyricum, a common soil bacterium that does
not produce false-positive tuberculosis test
results. Inflammatory responses to vaccines
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containing Freund’s Complete Adjuvant
(FCA) are more severe compared to those that
accompany AdjuVac (Powers et al. 2007). Lyda
et al. (2005) compared PZP antibody titers in
horses treated with PZP vaccines formulated
with either MFA or FCA and found consistently
greater antibody titers in the MFA vaccinated
group, although the diﬀerences were not
significant.
The
potential
eﬀect
of
PZP-based
immunocontraception on social structure and
behavior in herd animals has been explored
by Kirkpatrick et al. (1995) and Powell (2000),
who reported no diﬀerences among vaccinated
mares with respect to activity budgets,
hierarchy within the herd, or interactions with
stallions. However, Nuñez et al. (2010) found
that some PZP-treated mares foaled later in the
year and suggested that diﬀerences in habitat,
resource availability, and mare fitness aﬀects
their physiological and behavioral responses to
PZP contraception, which could ultimately also
aﬀect foal survivorship.
ZonaStat is a PZP-based vaccine that
requires a booster 3–4 weeks after the initial
inoculation and subsequent annual boosters to
maintain contraceptive eﬃcacy (Liu et al. 1989).
ZonaStat-H was approved by the EPA for use in
feral horses and burros in 2012, and ZonaStat-B
is a sub-label of the same vaccine approved for
use in white-tail deer (O. virginianus) in 2017. To
extend the duration of eﬃcacy without using
boosters, PZP-22 was developed. This product
uses timed-release pellets that contain PZP and an
adjuvant and are administered by hand injection
simultaneously with the primary vaccine dose.
It has a reported eﬃcacy of 22 months (Turner
et al. 2007). More recently, PZP-22 was delivered
by dart injection to a group of bait-trapped
mares, and the foaling rate was reduced by 79%
compared to controls during the first year but by
only 38% in the second year (Carey et al. 2017,
Rutberg et al. 2017). This level of performance
still does not meet the management needs of the
BLM (Roelle et al. 2017).

SpayVac
SpayVac was developed in the early 1990s as a
contraceptive vaccine to control the population
of grey seals (Halichoerus grypus) along the
Atlantic coast of Canada. As with other PZP
vaccines, SpayVac uses PZP glycoproteins as
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Table 1. Percent of grey seals (Halichoerus grypus) that were pregnant with and without SpayVac
VacciMax treatment on Sable Island, Nova Scotia, January 1992–1997 and 2002.
Fertility rates during years post-treatmenta
Years post-treatment

0

1

2

3

4

5

10

Control (n = 104)

100%

72%

70%

63%

71%

75%

70%

SpayVac (n = 101)

100%

47%

11%

9%

15%

12%

14%

Decreased fertility (%)

N/A

37%

85%

86%

79%

84%

80%

a

Years 0–5 data from Brown et al. 1997a; year 10 data from R. Brown, Immunovaccine, Inc., personal
communication.

the antigen along with an adjuvant such as
MFA or AdjuVac. Unlike ZonaStat, SpayVac
achieves multi-year eﬃcacy with a single dose,
without boosters, because the PZP antigens
are encapsulated within liposomes, which
gradually release PZP glycoproteins to antigenpresenting cells over an extended period of
time. Liposomes are multi-lamellar, concentric
spheres made up of phospholipid bilayers
separated by aqueous compartments and may
themselves be considered immunological
adjuvants (Allison and Gregoriadis 1974, Shek
and Sabiston 1982, Gupta et al. 1993). The
result is a longer-lasting, more robust immune
response that obviates the need for boosters for
several years.
Immunovaccine, Inc. (Halifax, Canada)
has developed patented liposome-based
formulations that improve the response of
the immune system to vaccines. VacciMax™
is a water-in-oil emulsion that has been
demonstrated to generate a significantly greater
immune response compared to that produced
by an alum-adjuvant vaccine (MacDonald et
al. 2010). DepoVax® is a novel antigen delivery
formulation that undergoes a lyophilization
step, with the components resuspended
in oil prior to injection, creating a unique
formulation that targets the immune system in
an active process (Brewer 2018). The DepoVax
formulation would have greater utility in the
field as a portable vaccine because it can be
lyophilized and subsequently reconstituted
when needed.
To explore ways to improve SpayVac,
formulations have been varied based on
diﬀerent amounts of PZP (ranging from 100–
400 μg PZP), type of adjuvant used (FCA,
MFA, or AdjuVac), and whether the vaccine
incorporated either the VacciMax or DepoVax
platform.

Immunovaccine, Inc. produced all SpayVac
formulations described in this paper. The PZP
was isolated as previously described by Brown
et al. (1997b) and incorporated in phosphate
buﬀered saline (pH 7.4). Lipids containing
lecithin and cholesterol at a ratio of 10:1 (0.2
g lecithin and 0.02 g cholesterol/dose) were
added to the PZP solution to form multilamellar
liposomes. For the VacciMax platform, the
prepared PZP liposomes mixture was combined
with MFA to form a water-in-oil emulsion.
For the DepoVax platform, the prepared
PZP-liposomes mixture was first lyophilized,
and then the lyophilized preparation was
reconstituted with MFA prior to administration.
Bicinchoninic acid-containing protein assays
and gel electrophoresis were used to control
quality. Standard bioburden testing according
to U.S. Pharmacopeia Convention (USP)
methods further ensured purity and safety of
vaccines.
Results from SpayVac trials in other species
can contribute to our understanding of how the
vaccine works, and how it might be successfully
applied to manage feral horse populations at
the AML. Below, we summarize results from
trials using diﬀerent formulations of SpayVac
in diﬀerent species, discuss the application of
this information, and consider management
implications and future research directions.

SpayVac in grey seals
Every January, grey seals gather in large
numbers to give birth, briefly nurse their pups,
and mate on Sable Island, which lies oﬀ the east
coast of Canada (Brown et al. 1997a). Following
a lactation period of just 2–3 weeks, the females
mate and depart the rookery.
It was during this brief period in January 1992
that 101 females were treated with SpayVac
VacciMax (100 μg PZP and FCA) and another
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104 females served as controls, receiving just
FCA and liposomes. All of the treated seals
had just given birth and were therefore proven
breeders, and because they had been branded
during an earlier population study, they were
of known age.
Because the seals were inoculated just 1–2
weeks before mating, there would not have
been enough time for PZP antibody titers to
fully develop, and no significant reduction
in fertility was expected during the first year
post-treatment (Table 1). During years 2–5 and
10 post-treatment, fertility rates in the control
animals ranged between 70–75%, while fertility
in the SpayVac-treated animals ranged from
9–15%, which was an 80–85% decrease. The
results during the first year post-treatment were
intriguing because there was a 37% reduction
in the number of pups produced by SpayVactreated seals.
In seals, development of the fertilized ovum
is arrested at the blastocyst stage, and only
later is it implanted in the uterus (Davies
1953). Perhaps PZP antibodies attached to
the ZP, which surrounds the blastocyst, and
subsequently interfered with implantation.
Normally, 25–30% of the seals that breed in any
given year will not breed in the next (Table 1).

SpayVac in deer
Overabundant populations of white-tailed
deer in urban and suburban areas contribute to
animal–vehicle collisions, disease transmission,
adverse impacts on other wildlife, and damage
to vegetation (McShea et al. 1997). In many
communities, hunting is not possible or
favored, making contraception an appealing
option for controlling population size. Because
of the lack of an eﬀective contraceptive vaccine,
Boulanger et al. (2012) took the extreme step
of surgical sterilization. However, because of
density-dependent changes in mortality and
survivorship, a large proportion (80% or more)
of a closed population needs to be captured and
treated to aﬀect a decline in numbers (Boulanger
et al. 2012). At roughly $1,000 per animal, this
process is very expensive and highly invasive
(Boulanger et al. 2012). Long-lasting, singledose immunocontraception oﬀers a more
economical and less invasive alternative.
Following the successful trial with seals
(Brown et al. 1997a), Fraker et al. (2002)
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conducted a field experiment with a freeranging population of fallow deer (Dama dama)
on James Island, British Columbia. Adult
females treated with SpayVac VacciMax (n = 41)
were followed for up to 3 years post-treatment
(Table 2). None of the treated females became
pregnant compared to 96% of the untreated
culled deer that served as controls; however,
due to accessibility challenges, only 19, 10, and
5 treated does were examined during years 1, 2,
and 3, respectively. The treated does apparently
continued to exhibit estrus because they were
observed being mounted by antlered males as
late as early April (the peak of the rut was late
October).
White-tailed deer have been the subject of
additional trials. The first of these took place
at the Johnson Space Center in Houston,
Texas, USA (Hernandez et al. 2006; Locke et al.
2007). Thirty-eight adult does were inoculated
with SpayVac VacciMax (Table 2), none of the
treated deer gave birth during the first 2 years
post-treatment (n = 32 and 20 for years 1 and
2, respectively, due to mortality losses), and
only 1 of 8 treated deer observed in year 3 gave
birth compared to 78–100% of control does that
fawned each year. Vaccination 1 month prior to
the breeding season provided enough time for
development of antibody titers and control of
fertility.
Another study, using captive white-tailed
deer in Pennsylvania, USA (Miller et al. 2009),
demonstrated contraceptive eﬃcacy of 80–100%
for 5 years with a single injection of SpayVac
VacciMax (Table 2; 1 doe fawned during years
4 and 5). In the same study, 4 does were treated
with an injection of SpayVac DepoVax, and half
of these does produced a fawn during year 3
(Table 2).

SpayVac in cats and elephants
SpayVac DepoVax and VacciMax formulations
have also been tested in domestic cats (Felis catus),
where high PZP-antibody titers were reported;
however, there was no reduction in litter size
(Gorman et al. 2002). Levy et al. (2005) used zona
pellucida isolated from cows (Bos taurus), cats,
ferrets (Mustela spp.), dogs, and mink (M. vison)
in SpayVac VacciMax with no eﬀect on fertility.
Bechert and Fraker (2016) vaccinated 6
captive African elephants with SpayVac (n = 3
with the VacciMax and n = 3 with the DepoVax
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Table 2. Percent of fallow (Dama dama) and white-tailed (Odocoileus virginianus) deer that were
pregnant with and without SpayVac treatment.
Deer species

Formulation

Treatment / control groups

% Fertile years post-treatment
1

a

2

3

100 μg PZP +
Fallow in
British Columbia FCA +
VacciMax

SpayVac (n = 41)
0 (n = 19)
Control (n = 111 average/year) 96

0 (n = 10)
97

0 (n = 5)
97

White-tailedb,c
in Texas

200 μg PZP +
AdjuVacd +
VacciMax

SpayVac (n = 38)
Control (n = 11 average/year)

0 (n = 32)
78

0 (n = 20)
78

13 (n = 8)
100

White-tailede
in Pennsylvania

200 μg PZP +
AdjuVac +
VacciMax

SpayVac (n = 5)
Control (n = 12 average/year)

0
100

0
100

0
100

200 μg PZP +
AdjuVac +
DepoVax

SpayVac (n = 4)
Control (n = 12 average/year)

0
100

0
100

50
100

a

Fraker et al. 2002
Hernandez et al. 2006
c
Locke et al. 2007
d
AdjuVac produced by the U.S. Department of Agriculture, National Wildlife Research Center,
Ft. Collins, Colorado, USA
e
Miller et al. 2009
b

formulation). The PZP antibody titers were first
detected 4 weeks post-vaccination but did not
peak until the end of year 1, after which they
remained consistently elevated through the
end of year 7 in most of the elephants (Bechert
and Fraker 2016). Elephants vaccinated with the
VacciMax formulation took longer to develop
antibody titers compared to the DepoVax
vaccination group. Additional research is needed
to determine actual contraceptive eﬃcacy and
potential long-term eﬀects on fertility in these
animals.

SpayVac in horses
The 3 trials conducted in horses used a variety
of SpayVac formulations and adjuvants (Table 3).
(Note that Gray et al. [2010] reported they had
used SpayVac on free-ranging horses, but this
was not accurate [Fraker and Brown 2011], and
Gray et al. [2011] subsequently corrected their
error).
In the first horse study, Killian et al. (2008)
observed pregnancy rates of 0, 17, 17, and 17%,
respectively, 1–4 years after treatment of mares
with a single SpayVac VacciMax dose (n = 12),
compared to 75, 75, 88, and 100% for untreated
mares (n = 8). Bechert et al. (2013) found that
3–4 months post-vaccination with SpayVac
VacciMax (n = 7) or DepoVax (n = 7), 93% of all
treated mares ceased cycling as evidenced by
lower serum concentrations of progesterone (P

< 0.025) and smaller ovaries with fewer follicles
(P < 0.001) compared to controls (n = 7), while
other organ systems were unaﬀected. This
was the first time such eﬀects on the ovaries of
horses had been studied.
A subsequent study in ponies, using a
diﬀerent PZP vaccine formulation (100 μg
PZP administered in the rump followed 5
weeks later by a 100 μg PZP booster injection;
n = 7), documented similar ovarian findings
based on transrectal ultrasound and basal
serum concentrations of progesterone (Joonè
et al. 2017a). Additionally, after breeding, all
PZP-treated mares were infertile compared to
100% fertility in the control group. The PZP
vaccination eﬀects on the ovaries were reversed
10 months after initiation of treatment (Joonè et
al. 2017a).
The third trial using SpayVac in horses
was conducted by the U.S. Geological Survey
using DepoVax (n = 30) and VacciMax (n = 30)
formulations administered in the rump (Roelle
et al. 2017; Table 3). These investigators found
that pregnancy rates for the VacciMax treatment
group were lower (P < 0.001) compared to
controls for 3 years following the single
injection. The fertility rate for the treated group
was 13, 47, and 43% compared to 100, 98, and
100% in controls for 1–3 years post-vaccination,
respectively. Although fertility in the mares
treated with the DepoVax formulation was only
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Table 3. SpayVac formulations and administration sites in horse (Equus caballus) trials.
Author

PZP dose

Formulation

Adjuvant

Injection site

Killian et al. 2008

400 μg

VacciMax

AdjuVac

Neck

Bechert et al. 2013

200 μg

VacciMax

MFA

Neck

DepoVax

MFA

Neck

VacciMax

MFA

Rump

DepoVax

MFA

Rump

Roelle et al. 2017

200 μg

17% in the first year, this increased to 76% in year
2, and this group was removed from the study.
The results observed by Roelle et al. (2017)
were not as robust as expected, given earlier
results from both Killian et al. (2008) and
Bechert et al. (2013). Diﬀerences in vaccine
formulations and injection sites (i.e., neck
versus rump) among these studies may account
for these variable results and are explored in
more detail below.
Neither Killian et al. (2008) nor Roelle et al.
(2017) found an absolute correlation between
antibody titer, measured by ELISA, and
infertility. In both cases, individual mares that
were consistently infertile did not necessarily
have the highest antibody titers, and the
ranges of titers observed in fertile and infertile
treated mares showed considerable overlap.
Previous studies have demonstrated a positive
correlation between levels of PZP antibodies
produced and contraceptive eﬀect (Liu et al.
1989, Turner et al. 1997), and similarly in the
Roelle et al. (2017) study, antibody titers in the
range of 50–60% of the positive reference serum
eﬀectively contracepted 90–95% of the mares.
The predominant antibody class in equine
serum and the major component of humoral
immunity is IgG. Horses have 7 diﬀerent IgG
isotypes (Wagner et al. 2004), and in a recent study
(Bechert and Wagner 2017) using serum samples
from VacciMax SpayVac-treated mares (n = 30) in
the Roelle et al. (2017) study, a fluorescent beadbased assay was used to distinguish IgG isotype
responses against PZP. The IgG1 antibodies
were generally higher in treated mares that were
infertile compared to those that were infertile, but
only IgG4/7 antibodies were significantly higher
in infertile mares during years 1 and 2 postvaccination (P < 0.05).
The IgG4/7 antibodies are produced in response
to many antigens, and responses are typically

long-lasting; thus, SpayVac’s potential ability to
preferentially stimulate IgG4/7 antibodies may
contribute to its long-term immunocontraceptive
eﬃcacy (Bechert and Wagner 2017). The
fluorescent bead-based assay increased the
analytical sensitivity to detect anti-PZP antibodies
compared to the ELISA, resulting in more
pronounced diﬀerences in antibody detection
between the fertile and infertile vaccinates.
Both Bechert et al. (2013) and Roelle et
al. (2017) reported vacillating reactions at
SpayVac injection sites in mares over a period
of months. These results suggested initiation
of a secondary immune response. The SpayVac
liposome platform likely resulted in prolonged
exposure to antigen. However, a key diﬀerence
between the Roelle et al. (2017) and earlier
Killian et al. (2008) and Bechert et al. (2013)
studies is the location of the injection site.
SpayVac vaccinations administered in the neck
were injected virtually on top of 1 of 2 primary
lymph nodes (the superficial cervical lymph
nodes), whereas vaccinations administered in
the rump (Roelle et al. 2017) may have been
injected into gluteal or hamstring muscles,
which were further from the nearest primary
lymph nodes (the subiliac).
There appears to be a direct correlation
between dendritic cell “input” into the lymph
and the “output” by the lymph node (Randolph
et al. 2005). Miller et al. (2009) first mentioned
the role that follicular dendritic cells in lymph
nodes may play in SpayVac’s eﬃcacy in whitetailed deer. Antigens that induce a strong
T-cell response initiate the mobilization and
maturation of dendritic cells, which migrate
into areas being assaulted. Follicular dendritic
cells are found primarily in lymph nodes
and the spleen, their receptors trap antigens
opsonized by complement or antibodies, and
they interact closely with B cells, which must
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bind the antigen presented by dendritic cells to
become future memory cells (Banchereau and
Steinman 1998).
SpayVac formulations seem to support
maturation and longevity of dendritic and
plasma cells in bone marrow (MacDonald et al.
2010). However, additional research is needed
to explore the potential impact that injection
site location may have on SpayVac’s eﬃcacy.
Most PZP vaccines are made with partially
purified porcine ZP, which is isolated from
pig (Sus domesticus) ovaries obtained from
slaughterhouses, and consequently, other
follicular proteins could potentially be involved
in eliciting ovarian responses in vaccinates
(Stoops et al. 2006). Dunbar et al. (1980) first
developed the mechanical PZP isolation
technique used today, whereby oocytes are
freed from cellular debris by sequential passages
of ground tissue in a buﬀer solution through a
series of nylon screens of decreasing pore size,
and a tissue homogenizer then releases the
ZP. They determined on a cellular basis that
extractions were 95% pure and were 93–97%
pure on an enzymatic basis, with cumulus
cells being the major cellular contaminant.
The antigens used to produce SpayVac derive
from a similar isolation procedure (Brown et al.
1997b), and the specificity of PZP antibodies in
the Bechert et al. (2013) study was demonstrated
by immunohistochemistry, as has been done in
other studies (Barber et al. 2001).
Western blot experiments have shown that
immune responses to PZP vaccination in mares
are against all of the PZP glycoproteins present
in partially purified vaccine formulations
(Liu et al. 2005); however, none of these tests
eliminates the possibility that other ovarian
proteins are also present. The presence of nonZP ovarian proteins is plausible (Mask et al.
2015), and this was further suggested by the
finding that recombinant ZP vaccines, which
include only specific glycoproteins comprising
an animal’s ZP (e.g., ZP3 is the glycoprotein in
mice responsible for sperm binding; Litscher
et al. 2009) do not have the same contraceptive
eﬀect elicited by native PZP (Miller et al. 2000,
Joonè et al. 2017b).
The ZP is composed of 3 or 4 major
glycoproteins that diﬀer among species in
protein structure and glycosylation, and this
may have contributed to species-specific
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diﬀerences seen in response to PZP vaccination
(Prasad et al. 2000). Antibodies produced in
response to PZP vaccination occupy spermbinding sites on the ova, thereby preventing
fertilization and/or interfering with egg
maturation within the follicle (Dunbar and
Schwoebel 1988). However, there may be other
roles that PZP antibodies play. For example, in
grey seals, the ZP surrounds the blastocyst and
may be involved in implantation, which may
explain the unexpected reduction in fertility
during the first year following vaccination, as
mentioned above.
Finally, dose (200 versus 400 μg PZP) and
adjuvant (AdjuVac versus MFA) may also aﬀect
SpayVac’s eﬃcacy. Although the Bechert et al.
(2013) study did not examine contraceptive
eﬃcacy, because 93% of the treated mares
stopped cycling, we believe that vaccination
probably rendered these mares infertile. Killian
et al. (2008) used 400 μg PZP and AdjuVac
instead of 200 μg PZP and MFA used by
Bechert et al. (2013), so these variables likely
play a minor role in SpayVac’s eﬃcacy.

Future research needs
We believe that SpayVac has great potential as
a long-term contraceptive agent for feral horse
population management in the United States
because it provides multi-year, single-dose
eﬃcacy. The manufacturers of SpayVac intend to
seek EPA regulatory approval to make it widely
available for use in horses and deer (http://www.
spayvac.com). However, research to explore
diﬀerences in immune response based on
injection site location and booster eﬀects is still
needed. Strengthening response to vaccination
by incorporating immune stimulants in the
formulation is also worth exploring (e.g., CpG;
Neeland et al. 2014). Roelle et al. (2017) stated,
“if even the modest results that we observed
[with SpayVac] could be duplicated on a large
scale…the BLM and other agencies charged
with managing feral horses would have a more
eﬀective fertility control tool than has heretofore
been available, especially given the fact that no
booster inoculation is required with SpayVac.”
A greater understanding of SpayVac’s
mechanism of action and long-term reproductive
eﬀects is needed so wildlife managers can
eﬃcaciously apply the vaccine to free-ranging
herds, possibly in conjunction with removals.
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To perfect the application of SpayVac, we
plan to investigate how the vaccine elicits its
immune response, considering diﬀerences
in PZP isolation methods, injection sites, and
formulations as well as the potential eﬀect of
boosters.
The time of year when vaccines are
administered likely makes a diﬀerence in
immune response, especially as related to health
and nutrition. Mares that have just come through
a rough winter might be expected to mount a
less robust immune response compared to mares
that are well fed, having spent the summer on
good range. Horses are seasonally polyestrous
long-day breeders, and during the winter,
anestrus is characterized by a flaccid uterus and
inactive ovaries. It generally takes 2 months for
peak antibody titers to develop, so vaccinating
mares a few months prior to the breeding season
(e.g., in the spring) should result in reliable
immunocontraception. However, because of its
multi-year eﬃcacy, SpayVac can be administered
to horses anytime during the year. Other factors,
such as environmental conditions that aﬀect
access to horses, may also have to be taken into
consideration by managers. If mares need to be
vaccinated while they are in anestrus, antibodies
to PZP will start binding to the ZP in emerging
follicles when the horses start cycling again.
Previous studies have demonstrated that
antibody titers in groups of horses and several
deer species can vary significantly in response
to vaccination with the same immunogen,
dose, and adjuvant (Kirkpatrick et al. 2011).
Abolins et al. (2011) demonstrated that wild
mice (Mus musculus) have more variable
immune responses than do laboratory mice
of the same species. Although a variety of
internal physiologic factors can influence an
animal’s ability to mount an immune response,
nutrition is key (Gross and Newberne 1980,
Ponton et al. 2011). For example, Nalder et
al. (1972) demonstrated that in rats (Rattus
norvegicus) vaccinated with tetanus toxoid, a
decrease in dietary quality (especially iron) of
only 10% results in a 50% decrease in antibody
titer. Therefore, also understanding how the
nutritional status, potential health challenges,
and environmental variables (e.g., interspecies competition, eﬀect of climate change
on vegetation) may aﬀect horse populations is
important when constructing a contraceptive
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vaccination strategy.
Additional research tools will be helpful
in implementing contraceptive population
management schemes. For example, the
fluorescent bead-based assay for anti-PZP
IgG4/7 detection could be used to establish
reliable cut-oﬀ values for IgG4/7 that are
eﬀective, and assessing ovarian function by
quantifying serum concentrations of antiMullerian hormone can further characterize
reproductive eﬀects of PZP vaccination (Joonè
et al. 2018).
We argue that the long-term population
eﬀects of immunocontraception should also
be considered when developing a vaccination
strategy. For example, studies with the
horse population on Assateague Island
have demonstrated a significant increase in
longevity of PZP-treated mares as compared
to controls because the continuing energy
demands of pregnancy and especially lactation
leaves untreated mares with lower body
condition scores and higher mortality rates
(Kirkpatrick and Turner 2007). Removals done
in conjunction with vaccinations may be needed
to most eﬀectively manage free-ranging horse
populations (Gross 2000, Garrott 2018).
Garrott (1991) optimistically estimated that
90% of the horses are detected when wildlife
managers determine population sizes. Given
the many variables described above, deciding
what proportion of a herd should be vaccinated
will not be easy. The BLM currently uses
the WinEquus population model for Herd
Management Area (HMA) planning (National
Research Council 2013). Model projections for
immunocontracepted horses on Assateague
Island predicted an average rate of population
decline of 13% per year, which suggested
that the management target of 80–100 horses
would be reached in 5–8 years (Ballou et al.
2008). Again, slow rates of population decline
have been attributed to reduced mortality
and increased longevity among treated mares
(Kirkpatrick and Turner 2008).
Good population models must consider an
animal’s life history, its social structure and
mating system, but also other factors that
could impact population dynamics like density
dependent variables and climate change (Garrott
2018). Climate change will also undoubtedly
aﬀect feral horse populations because many
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392:245–252.
currently live in arid habitats (Saltz et al. 2006).
Therefore, even once variables like vaccine Barber, M. R., S. M. Lee, W. L. Steﬀens, M. Ard,
and R. A. Fayrer-Hoskens. 2001. Immunolocalformulation and administration method,
ization of zona pellucida antigens in the ovarherd health and nutritional status, long-term
ian follicle of dogs, cats, horses and elephants.
population eﬀects, and population modeling
Theriogenology 55:1705–1717.
scenarios have been considered, contraceptive
strategies will need to be continually adjusted Bechert, U., J. Bartell, M. Kutzler, F. Menino, R.
Bildfell, A. Anderson, and M. Fraker. 2013.
through time.
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